The significant changes in medical care over the years, including advances in medicines and technology, are contributing to longer lifespans and higher costs of healthcare. CAR-T therapies are just the beginning of the advancements in cellular therapy for patients who have failed other cancer treatments. We believe the changes in technology and the high-touch care that is required with these treatments introduce a new level of unpredictability in costs and outcomes. At this time there are two approved drugs on the market: Kymriah (tisagenlecleucel: Novartis; invoice price of $475,000 for R/R ALL and $373,000 for R/R DLBCL Adult) and Yescarta (axicabtagene ciloleucel or axi-cel: Gilead/Kite; invoice price of $373,000). In addition to the invoice price, the nondrug costs can be as low as $80,000 to upwards of millions of dollars. The number of Food and Drug Administration (FDA) approved treatment facilities for Kymriah and Yescarta is expanding rapidly. LifeTrac has contract rates already in place with many treatment centers and can negotiate rates at the other treatment centers on a case-by-case basis to help you manage these high-cost drugs.
Let LifeTrac make difficult easier.
Cellular therapy requires a highly individualized regimen. LifeTrac is able to help you assess your members’ specific needs and work with the treatment center for your members’ care. The LifeTrac staff has the expertise to provide clinical and referral support to guide you through the process. From choosing a treatment facility to assisting with member services, LifeTrac can make difficult easier.
LifeTrac has compiled a list of CAR-T Therapy Codes to make difficult easier. Link to CAR-T Therapy Codes